Sept 22 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO :
* Bausch + Lomb and Nicox announce FDA acceptance of new drug application for novel glaucoma candidate Vesneo
* If approved, Vesneo will be the first nitric oxide donating prostaglandin receptor agonist available for the above indication
* Says Vesneo was licensed by Nicox to Bausch + Lomb
* FDA has set an action date of July 21 2016 to complete its review
* Source text for Eikon ID:nCNWfTQYza